83507-33-9

Basic information

• Product Name: 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE
• Synonyms: 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE;3-Benzyl-3-azabicylo[3.2.1]octan-8-one;3-Azabicyclo[3.2.1]octan-8-one, 3-(phenylMethyl)-;3-Benzyl-3-azabicyclo[3.2...;(1R,5S)-3-benzyl-3-azabicyclo[3.2.1]octan-8-one;3-(phenylmethyl)-3-Azabicyclo[3.2.1]octan-8-one
• CAS NO: 83507-33-9
• Molecular Formula: C₁₄H₁₇NO
• Molecular Weight: 215.29
• Product Categories: CHIRAL CHEMICALS
• Mol File: 83507-33-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 342.9°C at 760 mmHg
• Flash Point: 151°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 7.27E-05mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C
• PKA: 7.08±0.20(Predicted)
• CAS DataBase Reference: 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE(83507-33-9)
• EPA Substance Registry System: 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE(83507-33-9)

Safety Data

• Hazardous Substances Data: 83507-33-9(Hazardous Substances Data)

Usage

General Description

3-Benzyl-3-azabicyclo[3.2.1]octan-8-one is a chemical compound with the molecular formula C16H19NO. It belongs to the class of bicyclic organic compounds and is characterized by a bicyclic system containing a seven-membered ring and a six-membered ring fused together. 3-BENZYL-3-AZABICYCLO[3.2.1]OCTAN-8-ONE is also known as 8-Benzyl-3-aza-bicyclo[3.2.1]octan-3-one and is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. It has potential applications in the field of medicinal chemistry, where it can be used as a building block for the development of new drugs and therapeutic agents. Additionally, it may also have industrial applications as a chemical intermediate in the production of other organic compounds.

InChI:InChI=1/C14H17NO/c16-14-12-6-7-13(14)10-15(9-12)8-11-4-2-1-3-5-11/h1-5,12-13H,6-10H2

Upstream product

• 50-00-0 formaldehyd 
• 120-92-3 cyclopentanone 
• 100-46-9 benzylamine 
• 1019208-03-7 3-benzyl-1,5,3-dioxazepane 
• 1019208-04-8 3'-benzylspiro[1,3-dioxolane-2,8'-3-azabicyclo[3.2.1]octane] 
• 104247-86-1 N-benzyl-1-methoxy-N-(methoxymethyl)methanamine 

Downstream Products

• 521944-10-5 N-benzyl-3-azabicyclo[3.2.1]-8β-phenyloctan-8α-ol 
• 521944-19-4 N-benzyl-3-azabicyclo[3.2.1]-8β-(4-chloro)-phenyloctan-8α-ol 
• 521944-15-0 N-benzyl-3-azabicyclo[3.2.1]octan-8α-ol 
• 521944-12-7 3-azabicyclo[3.2.1]-8α-phenyloctane 
• 521944-14-9 3-azabicyclo[3.2.1]-8β-phenyloctan-8α-ol 
• 522608-86-2 rac-(1R,5S,8S)-3-benzyl-3-azabicyclo[3.2.1]octan-8-ol 
• 521944-11-6 N-benzyl-3-azabicyclo[3.2.1]-8α-phenyloctane 
• 521944-20-7 N-benzyl-3-azabicyclo[3.2.1]-8α-(4-chloro)phenyloctane 
• 521944-35-4 N-benzyl-3-azabicyclo[3.2.1]octane-8α-yl trifluoromethanesulfonate 
• 141380-34-9 octahydro-2,5-methano-2H-2-pyrindin-4-one 
• 141380-32-7 ethyl N-benzyl-3-azabicyclo<3.2.1>octane-8-carboxylate 
• 141380-36-1 3-(diphenylmethyl)octahydro-2,5-methano-2H-2-pyrindin-4-one 

Relevant articles and documents

5,6-Membered CNN palladium pincer complexes of 3-benzyl-8-dimethylamino -3-azabicyclo[3.2.1]octane and 3-benzyl-9-dimethylamino-3-azabicyclo[3.3.1]nonane

The unsymmetrical CNN pincer ligand precursors 4 and 7b based on the structures of bicyclo[3.2.l]octane and bicyclo[3.3.l]nonane have been synthesized. The corresponding palladium pincer 5,6-membered complexes 5 and 9 were prepared by direct cyclopalladat

INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

Muscarinic Receptor Antagonists

Provided are muscarinic receptor antagonists, which can be useful in treating various diseases of the respiratory, urinary or gastrointestinal system mediated through muscarinic receptors. Also provided are processes for preparing compounds described herein, pharmaceutical compositions comprising compounds described herein, and methods for treating diseases mediated through muscarinic receptors.